Technology | Advanced Visualization | February 08, 2019

Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

Advanced visualization software includes new applications for MRI, cardiology and endoscopy

Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

February 7, 2019 — Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information and Management Systems Society (HIMSS) global conference and exhibition, Feb. 11-15 in Orlando, Fla. The latest Synapse 3D Advanced Visualization software introduces five new applications, in addition to its current 50 clinical applications, that will be available for demonstration.

An enterprise-wide solution designed to quickly perform advanced visualization workflows and access 3-D rendered images, Synapse 3D boasts a total of 55 advanced applications, including five newly launched tools:

  • Breast Analyzer MR — A multi-faceted application that analyzes breast tumors in magnetic resonance imaging (MRI) and generates Breast Imaging-Reporting and Data System (BI-RADS) reports. It includes kinetic curves for wash-in and wash-out, and subtraction of pre- and post-contrast. The tool also performs a variety of measurements including distance from the nipple, distance from the skin, distance from the chest wall and tumor volume.
  • Delayed Enhancement MR — Designed with input from cardiologists, this application analyzes myocardial viability, provides delayed enhancement area and volume measurements, and displays the enhanced area overlaid in the bulls-eye map.
  • Endoscopic Simulator — With simulation now a key tool in training of physicians, this application was designed specifically for laparoscopic surgery simulation. It simulates inflation of the abdomen, port placement and positioning. The tool also offers the capability to automatically segment vessels, skin, bone, pancreas, spleen and tumors.
  • Intravoxel Incoherent Motion (IVIM) MR — The tool uses diffusion-weighted images to provide quantitative data from tissue microcapillary perfusion. It also automatically displays an ADC map, eADC map, D map, D* map and f map.
  • Prostate Viewer MR — A robust application to support prostate cancer diagnosis, this tool analyzes prostate gland tumors and generates Prostate Imaging-Reporting and Data System (PI-RADS) reports. It measures both diameter and volume of the prostate gland and lesions. It also features an array of viewing tools for comparative observation of multiple series, T2, ADC, DWI, DCE and time intensity curves.

In addition to these new applications, Synapse 3D delivers a comprehensive suite of applications consisting of general-use and specialty options for advanced image visualization and analysis. The software features Image Intelligence recognition technology that helps optimize processing capabilities, providing increased confidence in image assessment for providers. Designed with extensive clinical input, Synapse 3D incorporates intuitive, logical workflows that guide users to efficient and accurate results that can lead to improved patient outcomes.

For more information: www.fujimed.com

Related Content

Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Konica Minolta Healthcare Introduces New Financing Services Program for Exa Enterprise Imaging
News | Enterprise Imaging | June 17, 2019
June 17, 2019 – Konica Minolta Healthcare Americas Inc.
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
M*Modal and Community Health Network Partner on AI-powered Clinical Documentation
News | PACS Accessories | June 13, 2019
M*Modal announced that the company and Community Health Network (CHNw) are collaborating to transform the patient-...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Materialise Receives FDA Clearance for Cardiovascular Planning Software Suite
Technology | Advanced Visualization | June 13, 2019
Three-dimensional (3-D) printing software and solutions company Materialise has received U.S. Food and Drug...